Drug Approvals
Putting My Covered Call Strategy to Work With 2 Dinged Biotech Stocks
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
Exhaustion? Not Much Evidence Just Yet
The market may need some rest and consolidation, but that doesn't mean it will produce a lot of downside.
2 Small Biotechs to Put on Your 2020 Radar
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.
2 Biotech Stocks to Check Out After Karuna Therapeutics' Rocket-Like Surge
Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.
Differing Post-Earnings Tales of 2 Small-Cap Underachievers
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
3 Names Making the Case That Investing in Small Biotech Is Never Dull
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
2 Small Biotech Stocks Spurt Ahead on Positive Developments
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Big Biotech Receives Some Needed Shots in the Arm
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
Biogen Stock Soars on Alzheimer's Drug News
BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.